drugset / Trial / NCT02686151

The Letrozole Administration During Luteal Phase

NCT02686151

RandomizedParallel-groupOpen-labelPrevention

Summary

To investigate the effect of letrozole in patients who have high risk of ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval, the incidence of OHSS were calculated between letrozole group and supporting treatment group.

Timeline

Start
2023-12
Primary completion
2024-03
Completion
2024-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Letrozole Other / unclassified 5 mg Oral
Background Dexamethasone Small molecule 1 mg Intravenous
Background Polygeline Small molecule 500 ml Intravenous
Background sodium chloride Unknown 0.9 % Intravenous
Background sodium chloride Unknown 250 ml Intravenous